Carriers for the delivery of a vaccine against respiratory syncytial virus

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.5, Iss.7, 2005-07, pp. : 939-952

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Therapy of Respiratory Syncytial Virus by 2_5A Antisense

By Cramer Hagen Okicki James Kuang Mei Xu Zan

Nucleosides, Nucleotides & Nucleic Acids, Vol. 24, Iss. 5-7, 2005-04 ,pp. : 497-501

Taylor & Francis Ltd

Access to resources Recommend Favorite

Motavizumab for the prevention of respiratory syncytial virus infection in infants

By Gill Michelle A Welliver Robert C

Expert Opinion on Biological Therapy, Vol. 9, Iss. 10, 2009-10 ,pp. : 1335-1345

Informa Healthcare

Access to resources Recommend Favorite

Palivizumab in the prevention of respiratory syncytial virus disease

By Krilov Leonard R

Expert Opinion on Biological Therapy, Vol. 2, Iss. 7, 2002-10 ,pp. : 763-769

Informa Healthcare

Access to resources Recommend Favorite

A review of palivizumab and emerging therapies for respiratory syncytial virus

By Shadman Kristin A Wald Ellen R

Expert Opinion on Biological Therapy, Vol. 11, Iss. 11, 2011-11 ,pp. : 1455-1467

Informa Healthcare

Access to resources Recommend Favorite

Antisense approaches for inhibiting respiratory syncytial virus

By Cramer Hagen

Expert Opinion on Biological Therapy, Vol. 5, Iss. 2, 2005-02 ,pp. : 207-220

Informa Healthcare

Access to resources Recommend Favorite